xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Congestion
Conditions
Nasal Congestion
Trial Timeline
Feb 26, 2018 → May 2, 2018
NCT ID
NCT03439436About xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic
xylo+dex nasal spray (0.1 mg+5 mg/dose) + Nasic is a phase 3 stage product being developed by Johnson & Johnson for Nasal Congestion. The current trial status is completed. This product is registered under clinical trial identifier NCT03439436. Target conditions include Nasal Congestion.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03439436 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Congestion